Latest news with #PetVivoHoldings
Miami Herald
15 hours ago
- Business
- Miami Herald
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
This week's episode is sponsored by The Sustainable Green Team's Waterless Garden (OTC:SGTM) and PetVivo Holdings, Inc.'s (NASDAQ:PETV) innovative SPRYNG™ product. NEW YORK CITY, NY / ACCESS Newswire / June 14, 2025 / New to The Street, the nationally syndicated business television series known for spotlighting innovation across sectors, announces the premiere of Episode #671 airing tonight on Bloomberg Television at 6:30 PM EST. This week's broadcast features five dynamic companies making waves across blockchain, AI, health tech, wellness, and pharmaceutical sectors: FLOKI - The globally recognized crypto and blockchain brand building Web3 utility through its DeFi AI (NASDAQ:ARAI) - Developer of a patented smart mailbox delivery platform, leading last-mile logistics innovation with its autonomous, AI-powered In Tech (NASDAQ:HIT) - A pioneer in digital underwriting and quote-to-card technology for health insurance, transforming how plans are built and Bella - A wellness brand that continues to expand its national presence through health-focused lifestyle Pharmaceuticals (NASDAQ:NRXP) - A late-stage pharmaceutical company advancing treatments for CNS disorders and respiratory distress. This week's featured corporate sponsors include: The Sustainable Green Team (OTC:SGTM) and its revolutionary Waterless Garden initiative for drought-resistant, sustainable Holdings, Inc. (NASDAQ:PETV), showcasing continued progress with its SPRYNG™, a veterinary injectable device for treating osteoarthritis in companion animals. Upcoming Highlights:New to The Street has also wrapped filming this week with several prominent brands: GLINT Pay (Private) - A disruptive gold-as-money platform allowing real-time gold Gold Corp. (TSX.V:LG / OTCQB:LGCXF) - Canadian gold exploration company with high-grade assets in Consulting Group - Providing strategic solutions across regulatory compliance, M&A, and executive Feature Segment: A culinary showcase from two of New York City's most iconic dining destinations - Black Barn and Hunt & Fish Club - blending luxury hospitality with the business of restaurant branding. Additionally, special segments fromIMG Academy, Skip Barber Racing School, and KITON will continue to roll out in the coming months as part of New to The Street's ongoing coverage of elite performance, luxury, and innovation. Quote from Vince Caruso, Creator and Executive Producer of New to The Street: About New to The StreetSince 2009, New to The Street has become one of the most trusted platforms for public and private companies to share their stories. The show combines sponsored programming with earned media, enhanced by iconic outdoor campaigns, nationwide TV commercials, and non-deal roadshows that connect executives with top-tier investors and institutions. With weekly reach across 220 million linear TV households, a growing 2.65 million YouTube subscribers, and a robust social media presence exceeding 700,000 followers across LinkedIn, Facebook, Instagram, and X, New to The Street delivers unparalleled exposure and credibility in the business media space. Media Contact:Monica BrennanPR & Media RelationsMonica@ For more information, visit SOURCE: New To The Street
Indianapolis Star
2 days ago
- Business
- Indianapolis Star
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
This week's episode is sponsored by The Sustainable Green Team's Waterless Garden (OTC:SGTM) and PetVivo Holdings, Inc.'s (NASDAQ:PETV) innovative SPRYNG™ product. NEW YORK CITY, NY / ACCESS Newswire / June 14, 2025 / New to The Street, the nationally syndicated business television series known for spotlighting innovation across sectors, announces the premiere of Episode #671 airing tonight on Bloomberg Television at 6:30 PM EST. This week's broadcast features five dynamic companies making waves across blockchain, AI, health tech, wellness, and pharmaceutical sectors: FLOKI – The globally recognized crypto and blockchain brand building Web3 utility through its DeFi ecosystem. Arrive AI (NASDAQ:ARAI) – Developer of a patented smart mailbox delivery platform, leading last-mile logistics innovation with its autonomous, AI-powered systems. Health In Tech (NASDAQ:HIT) – A pioneer in digital underwriting and quote-to-card technology for health insurance, transforming how plans are built and priced. Vita Bella – A wellness brand that continues to expand its national presence through health-focused lifestyle offerings. NRX Pharmaceuticals (NASDAQ:NRXP) – A late-stage pharmaceutical company advancing treatments for CNS disorders and respiratory distress. This week's featured corporate sponsors include: The Sustainable Green Team (OTC:SGTM) and its revolutionary Waterless Garden initiative for drought-resistant, sustainable landscaping. PetVivo Holdings, Inc. (NASDAQ:PETV), showcasing continued progress with its SPRYNG™, a veterinary injectable device for treating osteoarthritis in companion animals. Upcoming Highlights: New to The Street has also wrapped filming this week with several prominent brands: GLINT Pay (Private) – A disruptive gold-as-money platform allowing real-time gold transactions. Lahontan Gold Corp. (TSX.V:LG / OTCQB:LGCXF) – Canadian gold exploration company with high-grade assets in Nevada. Greer Consulting Group – Providing strategic solutions across regulatory compliance, M&A, and executive strategy. Special Feature Segment: A culinary showcase from two of New York City's most iconic dining destinations – Black Barn and Hunt & Fish Club – blending luxury hospitality with the business of restaurant branding. Additionally, special segments fromIMG Academy, Skip Barber Racing School, and KITON will continue to roll out in the coming months as part of New to The Street's ongoing coverage of elite performance, luxury, and innovation. Quote from Vince Caruso, Creator and Executive Producer of New to The Street: 'We continue to be a destination for innovative and publicly traded companies ready to tell their story at scale. Tonight's show blends AI, healthcare, crypto, and wellness with real national TV exposure. We're proud to feature these brands and grateful to our show sponsors for helping amplify their messages.' About New to The Street Since 2009, New to The Street has become one of the most trusted platforms for public and private companies to share their stories. The show combines sponsored programming with earned media, enhanced by iconic outdoor campaigns, nationwide TV commercials, and non-deal roadshows that connect executives with top-tier investors and institutions. With weekly reach across 220 million linear TV households, a growing 2.65 million YouTube subscribers, and a robust social media presence exceeding 700,000 followers across LinkedIn, Facebook, Instagram, and X, New to The Street delivers unparalleled exposure and credibility in the business media space. For more information, visit SOURCE: New To The Street View the original press release on ACCESS Newswire
Yahoo
22-05-2025
- Business
- Yahoo
Petvivo Holdings, Inc. and PiezoBioMembrane Inc. Announce Master Services Agreement to Jointly Develop Innovative Functional Biomaterials
MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively referred to herein as the "Company" or 'PetVivo') an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for animals, and PiezoBioMembrane, Inc ('PiezoBio')., a pioneer in biodegradable piezoelectric materials intended for implantable applications, today announced a transformative Master Services Agreement. The strategic partnership centers on collaborative research and development of revolutionary functional biomaterials that include piezoelectric nanofibers incorporated into a biocompatible biomaterial comprised of natural materials that mimics mammalian extracellular matrix ('ECM'). We believe these functional biomaterials can be biologically activated by piezoelectric stimulation to promote regeneration and/or remodeling of damaged or injured tissue and bone in animals and humans. Partnership Structure and Strategic Benefits Under the Master Services Agreement, PetVivo and PiezoBio will collaboratively work to combine PetVivo's ECM biomaterial with PiezoBio's piezoelectric nanofibers. The anticipated piezo-biomaterial derived from this collaboration is intended to have functional attributes that can be biologically activated, thereby promoting enhanced healing, regeneration and/or remodeling of damaged or injured mammalian tissue and bone. PetVivo has developed and is commercializing a biocompatible biomaterial that mimics mammalian tissue. The Company has recognized the many advantages of matching the composition of implantable biomaterials to the native tissue surrounding the implant site and the importance of creating biomatrix materials that exhibit limited to no adverse effects when placed in the body of an animal or human. PetVivo has successfully created a biomaterial that is included in several new product lines that possess these assimilating and biocompatible properties. One example of PetVivo's biocompatible, ECM-like products is SPRYNG® with OsteoCushion® Technology. Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis. Mike Eldred, Board Member of PetVivo Holdings, Inc. said, "PetVivo has been developing the next-generation of biomaterials that mimic mammalian tissue using all-natural components, which are commonly found in the extracellular matrix of animals and humans. We aim to leverage our in-house biomaterial expertise, along with the exceptional piezoelectric material expertise of PiezoBio, to develop the next generation of functional biomaterials. This collaboration with PiezoBio will enable us to advance our research and potentially result in innovative medical devices and therapeutics that can be transformative for veterinarians and their patients." PiezoBio has developed a biodegradable piezoelectric nanomaterial that can act as a battery-less electrical stimulator to promote enhanced cell activity when implanted in mammalian tissue or bone. The technology provides, for the first time, (1) a wireless, battery-free and self-stimulated technology to generate electrical stimulation for inducing tissue/bone regeneration, (2) a tool to systematically study interaction between cells and surface charge for tissue/bone regeneration, and (3) an approach to design and create a novel nanomaterial-based biodegradable piezoelectric scaffold which can form highly-regenerative replacement for treatment of damaged or injured tissue and bone. "We expect that this collaboration will generate synergy by combining PetVivo's experience in developing biocompatible biomaterials made from natural materials and our expertise in piezoelectric materials that promote therapeutic healing and regeneration," said Linh Le, Chief Executive Officer at PiezoBioMembrane, Inc. "Through open innovation, we aim to actively expand our development efforts beyond our core areas related to piezoelectric materials to enhanced functional biomaterials that may be used in a multitude of therapeutic fields." For more information about PetVivo Holdings, Inc. and our revolutionary products, Spryng with OsteoCushion Technology and PrecisePRP, please contact info1@ or visit or For more information about PiezoBioMembrane, Inc. and our revolutionary piezoelectric material platform, please contact hello@ or visit About PetVivo Holdings, Inc. PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale. CONTACT: John Lai, CEO PetVivo Holdings, Inc. Email: info1@ (952) 405-6216 About PiezoBioMembrane, Inc. PiezoBio is engaged in the research, development, and manufacturing of piezoelectric biomaterials for healthcare applications. The company is committed to harnessing innovative science and technology to deliver impactful solutions that advance both human and animal health. As a spin-off from the University of Connecticut, PiezoBio pursues strategic partnerships to accelerate product development and reduce time-to-market. CONTACT: Linh Le, CEO PiezoBioMembrane, Inc. Email: hello@ Forward-Looking Statements: The foregoing material may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as 'may,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'believe,' 'potential,' 'should,' 'continue' or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
DIGITAL LANDIA, LLC IN COOPERATION WITH PETVIVO HOLDINGS, INC. UNVEILS REVOLUTIONARY AUTONOMOUS PET AI ECOSYSTEM TRANSFORMING PET CARE WITH SELF-LEARNING MULTI-AGENT AI TECHNOLOGY
MIAMI, FL, May 13, 2025 (GLOBE NEWSWIRE) -- Digital Landia, LLC, in cooperation with PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly owned subsidiary PetVivo Animal Health, Inc. (collectively referred to herein as "PetVivo"), today announces the upcoming launch of the world's first autonomous pet care AI ecosystem that leverages cutting-edge multi-agent technology to revolutionize how we understand and care for our animal companions. Set for public release on May 23, 2025, this groundbreaking platform creates specialized AI agents that continuously learn and evolve to provide unprecedented insights into pet health and wellness. " represents a paradigm shift in pet care technology," said Karim Quazzani, CEO of Digital Landia. "By creating an ecosystem of self-learning AI agents that collaborate as an interconnected swarm, we're enabling pet owners to understand their companions in ways previously unimaginable. Furthermore, we're building more than just another pet app; is creating a new category of intelligent pet care that will continuously evolve to meet the needs of veterinarians, pets and their owners." Breakthrough Self-Creating AI Technology Unlike conventional pet care applications, framework autonomously spawns specialized AI agents that "graduate" through rigorous digital certification exams. These super agents achieve expert-level mastery in veterinary diagnostics, behavior analysis, nutrition, and more. The system continuously adapts by creating new agents based on incoming pet data, ensuring relevance across evolving health, behavioral, and environmental variables. Comprehensive Pet Care Through Specialized Agents The platform features an impressive array of specialized AI agents working in concert: Veterinary Diagnostics Agent: Assesses overall pet health using imaging, lab results, and sensor data; Behavioral Analysis Agent: Interprets pet behavior using video and audio feeds to identify stress, anxiety, or other issues; Nutritional Advisor Agent: Delivers personalized dietary plans by integrating scientific research with individual pet needs; Emotional Wellness Agent: Evaluates a pet's emotional state through advanced audio analysis and facial expression recognition; and IoT Data Integration Agent: Acts as a hub for real-time sensor data, preparing for next-generation integration with devices capturing vital signs and biometric measurements. Real-World Applications That Transform Pet Ownership brings remarkable capabilities to everyday pet care scenarios: The Pet Translator: Decodes subtle cues like tail movements, blinking patterns, and vocal intonations to communicate messages such as "Bella is feeling slightly anxious today'; Early Disease Detection: Identifies minute changes in gait, posture, or behavior that might indicate developing health conditions before they become serious; and Comprehensive Wellness Reports: Aggregates data across multiple dimensions to provide holistic health insights and proactive care recommendations. Innovative Business Model will launch with a tiered pricing structure designed to make this revolutionary technology accessible to pet owners everywhere: Freemium Tier: Entry-level access with limited tokens to experience the platform; Premium Subscription ($9.95/month): Multiple pet profiles with on-demand access to individual AI agents; and Elite Package ($24.95/month): Comprehensive access to the full AI swarm for in-depth pet wellbeing reports. The platform also features innovative B2B integration through proprietary MCP/Gibberlink protocols, allowing veterinary practices, pet care providers, and pet product companies to communicate directly with pet owners' AI agents. Growth Trajectory With a proven track record of onboarding over 270,000 users in previous ventures, Digital Landia projects 100,000 freemium users within six months of launch. Conservative estimates suggest a 10% conversion to paid subscriptions, generating nearly $2 million in annual recurring revenue. ' represents a major advance in how we understand our pets,' said John Lai, CEO of PetVivo Holdings, Inc. 'By aligning clinically proven therapies, like Spryng® with OsteoCushion® Technology and PrecisePRP, with this very powerful AI technology, we position PetVivo at the intersection of AI innovation and veterinary care. We anticipate Pet AI will provide an incredibly valuable resource to veterinarians and pet owners alike, as well as, create unparalleled visibility for PetVivo brands, including SPRYNG and PrecisePRP.' About Digital Landia Digital Landia specializes in developing cutting-edge AI solutions that bridge the gap between advanced technology and everyday needs. The company is dedicated to creating accessible, practical applications of artificial intelligence that enhance quality of life. Contact Information: Karim Quazzani Team@ 'For more information about PetVivo Holdings, Inc. please contact info1@ or visit and About PetVivo Holdings, Inc. PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale. Contact Information: John Lai, CEO PetVivo Holdings, Inc. Email: info1@ (952) 405-6216 Forward-Looking Statements: The foregoing material may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as 'may,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'believe,' 'potential,' 'should,' 'continue' or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-02-2025
- Business
- Yahoo
PetVivo Reports Fiscal Q3 2025 Results
MINNEAPOLIS, MN, US, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutics and medical devices for equines and companion animals, reported results for its fiscal third quarter ended December 31, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call today at 3:00 p.m. Eastern time to discuss the results for the period (see dial-in information below). Fiscal Q3 2025 Financial Highlights Revenues totaled $583,000, up 191% sequentially and declined 2% from the same year ago period, reflecting the company's continued efforts from targeting primarily the equine market to include at a greater scale the much larger companion animal market. These efforts have involved a realignment and expansion of the company's sales force, with this producing an increased portion of sales related to companion animals in the past few quarters. Nationwide distributor network sales totaled $545,000, up 222% sequentially and relatively consistent from the same year ago period. Gross profit declined 2% to $522,000, with gross margin maintained at a highly favorable 89.5%. Operating loss totaled $1.8 million, improving by $375,000. The large reduction was due to the company's strategic corporate restructuring and cost reduction program. Net loss totaled $1.76 million or $(0.09) per basic and diluted share, as compared to a net loss of $1.75 million or $(0.12) per basic and diluted share in the same year-ago quarter. Fiscal Q3 2025 Operational Highlights Continued to expand the distribution network of PetVivo's lead animal osteoarthritis medical device, Spryng® with OsteoCushion® Technology has been used by more than 800 veterinary clinics across all 50 states since its introduction to the veterinary market. Substantial accumulation of data for elbow osteoarthritis canine study with principal investigators from Orthobiologic Innovations, a leader in R&D for regenerative and sports medicine. Appointed Cindy Gill to the position of field veterinary business development manager for Oklahoma and Arkansas and the northern region of Texas. Hired two experienced sales representatives and a technical service veterinarian to support the company's territory managers. Exhibited at two major veterinary conferences: American College of Veterinary Surgeons Surgery Summit and American Association of Equine Practitioners convention. Management Commentary 'During the fiscal third quarter, we continued to expand our nationwide distribution network for our lead animal osteoarthritis medical device, Spryng with OsteoCushion™ Technology,' commented PetVivo CEO, John Lai. 'Since this revolutionary device's introduction to the market in the fall of 2021, it has now been used by more than 800 veterinary clinics across all 50 states. The nationwide expansion of our distribution network helped drive a 191% sequential quarterly increase in revenues to $583,000, with our nationwide distributor network sales contributing $545,000 of this total. Our fiscal third quarter is also typically the largest quarter of the year, with this mostly due to the exposure we receive at major veterinary conferences that occur during the period. While total revenues increased sequentially, they declined 2% from the same year ago period. This reflects our continued endeavors in focusing a greater effort towards the much larger companion animal market. Our team is now focused upon expanding both the equine and small animal markets going forward. The increased emphasis on the small animal market has involved a realignment and expansion of our sales force, with this resulting in an increased portion of sales related to companion animals in the third quarter. Meanwhile, we've been able to maintain our very favorable high gross margins of 89.5%. To further accelerate our growth, we have added a number of territory managers, as well as some highly experienced sales representatives and another senior technical services veterinarian to support our territory managers. These internal sales reps and technical services veterinarian are also supporting our direct sales and marketing to leading veterinary clinics. We have also enhanced our leadership talent with the appointment of Mike Eldred as a Director to assist in the Company's operations and commercialization; Mr. Eldred was appointed to the Board in September, 2024. In this appointment, Mr. Eldred has been asked to assume the tasks and responsibilities of a Commercial and Operations Advisor. Mr. Eldred built Dechra's North American subsidiary from the 'ground up' to become one of the fastest growing companies in the industry, with more than 250 employees and revenue in excess of $450 million. Mr. Eldred's experience and strong record of business achievement in pharmaceutical and animal health brings to our company a tremendously valuable resource for achieving our business goals. A key aspect of our strategy to drive greater adoption of Spryng is to expand the awareness of its effectiveness and benefits among key decision-makers, and do this at an increasingly greater scale. To support this effort, we participated in two major veterinary conferences last quarter, along with several smaller industry events. In October, we exhibited at the American Association of Equine Practitioners Convention Surgery Summit, where we demonstrated Spryng to leading veterinarian surgeons. Furthermore, in December we participated in the American College of Veterinary Surgeons Surgery Summit, where Spryng was on display to the equine veterinary community. Finally, in January, we presented Spryng to a large number of veterinarian practitioners at the Veterinary Meeting & Expo Conference or VMX. VMX is the largest veterinary conference in the U.S. and hosts many of the industry's top professionals. These events were great opportunities to demonstrate the advantages of Spryng, and the beneficial results we have seen when administered to horses and companion animals, both anecdotally and in numerous clinical studies. During the third fiscal quarter, we continued the accumulation of data for our canine elbow study being conducted with Orthobiologic Innovations, a leader in R&D for regenerative and sports medicine. The study is being led by prominent veterinarians, Sherman and Debra Canapp and we expect it to be fully completed within the new few quarters. In addition to pursuing new clinical trials for Spryng, the experts at Orthobiologic Innovations are also supporting our product development and marketing. Studies like the canine elbow study, as well as our completed studies related to the management of stifle cranial cruciate ligament disease and hip osteoarthritis, play a crucial role in our distribution strategy, as large national and international distributors often require university or independently conducted research before adding a new product like ours to their catalog. With our already completed clinical studies, we believe we have sufficient data to secure large corporate clients who have extensive veterinary clinic networks nationwide. We estimate about 75% of veterinary clinics are owned by such major corporate groups, and we anticipate engaging several of them regarding the use of Spryng in the upcoming quarters. We also announced in the third quarter new distribution partnerships with Vedco and Clipper Distributing -- both leaders in logistical solutions and product supply to veterinarians. Vedco and Clipper distribute to many of the largest national veterinary product distribution entities in the U.S., including MWI, Covetrus, Patterson, Midwest Supply and Penn Supply -- just to name a few. With these distribution partnerships, we can help ensure that veterinarians across the country have easy access to Spryng. Altogether, with our expanding distributor network, the completion of additional clinical studies, and our more efficient operational structure, we believe we are more well-positioned than ever to accelerate our growth over the next year and beyond. The expansion of our distribution network also means we are in the strongest position to capitalize on the vast opportunities in U.S. animal health marketplace, which today totals more than $5.7 billion …and is projected to double to $11.3 billion by 2030. Another key milestone for the Company has been the signing of an exclusive licensing and supply agreement with VetStem, Inc. This partnership provides PetVivo the right to commercialize VetStem's proprietary allogeneic platelet rich plasma ('PRP') product for horses and dogs, PrecisePRP®. We are thrilled by the opportunity to work with this revolutionary product and VetStem's team of professionals. As we grow, we will remain committed to advancing pet health solutions and ensuring that our products reach more veterinary professionals and pet owners. We look forward to building on these advancements as we continue to strengthen our market presence and drive greater value for our stakeholders.' Fiscal 2025 Revenue Outlook For the company's full fiscal year 2025 ending March 31, 2025, it appears that its outlook for net revenue to total approximately $1.1 million. This would represent growth of approximately 10% over the prior year. Given this growth and the realignment in sales and marketing, combined with decreases in certain operating expenses, the company also expects an improved bottom line for the fiscal year. Fiscal Q3 2025 and Fiscal First Nine Months of 2025 Financial Summary Revenues in the fiscal third quarter of 2025 decreased 2% to $583,000, largely due to decreased direct sales to veterinary clinics as the company transitions to greater use of its expanding distribution network. Sales to distributors were relatively consistent in the quarter during this transitional period, with the anticipated longer-term benefit of more rapid sales growth and market expansion. Gross profit totaled $522,000 or 89.5% of revenues, compared to $533,000 or 89.5% of revenues in the same year-ago period. Revenues in the fiscal first nine months of 2025 declined 1% to $908,000 compared to $920,440 in the same year-ago period. Gross profit totaled $812,000 or 89.5% of revenues in the first nine months of 2025, compared to $824,000 or 89.5% of revenue in the same year-ago period. Operating expenses for the nine months ending December 31, 2024, decreased by $2 million (23%) from the same nine months period ending on December 31, 2023. The expense reduction was due to a strategic company-wide cost reduction and restructuring program that has decreased general and administrative expenses by $1 million, and a reduction of sales and marketing expenses by $1.2 million versus the same nine months a year-ago. The decreases were partially offset by an increase in R&D of $220,000 due to the performance of clinical trials to support the underlying science behind our Spryng product. For the nine months ending, our net loss totaled $6 million or $(0.30) per basic and diluted share, which was $2.3 million less net loss of $8.3 million or $(0.64) per basic and diluted share in the same nine-month period a year-ago. Net loss for the third quarter totaled $1.76 million or $(0.09) per basic and diluted share compared to a net loss of $1.75 million or $(0.12) per basic and diluted share in the same year-ago quarter. Cash and cash equivalents totaled totaled $29,000 at December 31, 2024. To improve our cash position, from the end of the quarter we completed a capital raise with net proceeds of approximately $1.1 million. We expect these funds to keep the company on track to execute our growth strategies over the next few months. As a result of this recent raise, our cash and cash equivalents currently total approximately $418,000. Our net cash used in operating activities for the nine months ending December 31, 2024, decreased 31% or $1.8 million compared to the same nine-months period ending December 31, 2023, demonstrating how we have become more efficient and cost-wise with our cash spending and company-wide cost cutting program. For a more detailed overview of the company's financials, see PetVivo Holdings' consolidated statements of operations and consolidated balance sheet, below. Conference CallPetVivo will host a conference call today to discuss these results, which will include a question-and-answer period. Date: Friday, February 14, 2025Time: 2:00 p.m. CST (3:00 pm EST)Dial-in: +1 253 215 8782Meeting ID: 84361016783Passcode: 632113Webcast (live and replay): here A replay of the webcast will be available through the same link following the conference call. The conference call webcast is also available via a link in the Investors section of the company's website at About PetVivo HoldingsPetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics. PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company's commercially launched flagship product, Spryng® with OsteoCushion® Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses. For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@ or visit or Disclosure InformationPetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company's Investor Relations website, in addition to following the company's press releases, SEC filings, public conference calls, presentations and webcasts. Forward-Looking commercial StatementsThe foregoing information regarding PetVivo Holdings, Inc. (the 'Company') may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as 'may,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'believe,' 'potential,' 'should,' 'continue' or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactJohn Lai, CEOPetVivo Holdings, ContactTel (952) 405-6216 PETVIVO HOLDINGS, BALANCE SHEETS(UNAUDITED) December 31, 2024 March 31, 2024 (Unaudited) Assets: Current Assets Cash and cash equivalents $ 28,891 $ 87,403 Accounts receivable 493,121 18,669 Inventory, net 353,307 390,076 Prepaid expenses and other assets 351,510 545,512 Total Current Assets 1,226,829 1,041,660 Property and Equipment, net 770,267 821,656 Other Assets: Operating lease right-of-use 1,055,150 1,194,348 Trademark and patents, net 25,104 30,099 Security deposit 34,990 27,490 Total Other Assets 1,115,244 1,251,937 Total Assets $ 3,112,340 $ 3,115,253 Liabilities and Stockholders' Equity: Current Liabilities Accounts payable $ 1,028,679 $ 821,230 Accrued expenses and other payables 410,056 243,030 Operating lease liability – short term 191,766 190,589 Note payable and accrued interest 1,305,813 157,521 Total Current Liabilities 2,936,314 1,412,370 Other Liabilities Operating lease liability (net of current portion) 863,384 1,003,759 Note payable and accrued interest (net of current portion) 7,423 13,171 Total Other Liabilities 870,807 1,016,930 Total Liabilities 3,807,121 2,429,300 Commitments and Contingencies Stockholders' Equity: Series A Preferred Stock, par value $0.001, 20,000,000 shares authorized, 3,045,000 and zero issued and outstanding at December 31, 2024 and March 31, 2024, respectively 3,045 - Common Stock, par value $0.001, 250,000,000 shares authorized, 21,251,784 and 17,058,620 issued and outstanding at December 31, 2024 and March 31, 2024, respectively 21,252 17,059 Additional Paid-In Capital 88,059,840 83,468,218 Accumulated Deficit (88,778,918 ) (82,799,324 ) Total Stockholders' Equity (694,781 ) 685,953 Total Liabilities and Stockholders' Equity $ 3,112,340 $ 3,115,253 PETVIVO HOLDINGS, STATEMENTS OF OPERATIONS(UNAUDITED) Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Revenues $ 583,313 $ 595,891 $ 907,783 $ 920,440 Cost of Sales 61,497 62,569 95,653 96,646 Gross Profit 521,816 533,322 812,130 823,794 Operating Expenses: Sales and Marketing 723,461 1,032,575 1,878,180 3,053,184 Research and Development 371,953 351,584 1,224,642 1,004,780 General and Administrative 1,184,807 1,282,787 3,685,186 4,737,374 Total Operating Expenses 2,280,221 2,666,946 6,788,008 8,795,338 Operating Loss (1,758,405 ) (2,133,624 ) (5,975,878 ) (7,971,544 ) Other (Expense) Income Loss on Extinguishment of Debt - - - (534,366 ) Settlement Expense - - - (180,000 ) Extinguishment of payables - 385,874 - 385,874 Other Income (Expense) 25,745 - 25,745 - Interest (Expense) Income (24,378 ) (2,098 ) (29,461 ) (4,542 ) Total Other (Expense) Income 1,367 383,776 (3,716 ) (333,034 ) Loss before taxes (1,757,038 ) (1,749,848 ) (5,979,594 ) (8,304,578 ) Income Tax Provision - - - - Net Loss $ (1,757,038 ) (1,749,848 ) (5,979,594 ) (8,304,578 ) Net Loss Per Share: Basic and Diluted $ (0.09 ) (0.12 ) (0.30 ) (0.64 ) Weighted Average Common Shares Outstanding: Basic and Diluted 20,632,921 14,271,530 19,786,608 12,976,851 Sign in to access your portfolio
